Abstract
Correction for ‘Antibody recruiting molecules (ARMs): synthetic immunotherapeutics to fight cancer’ by Silvia Achilli et al., RSC Chem. Biol., 2021, 2, 713–724. DOI: 10.1039/d1cb00007a.
The authors regret mistakes in the structures depicted in Table 1, entry A and Table 2, entry B. The correct version of both tables are shown below. The conclusions of the paper have not been affected.
Examples of ARMs against cancer cells.
| Entry | Tumor target | ARM valency | ABM | TBM | ARM structure |
|---|---|---|---|---|---|
| A41 | uPAR | Mono | DNP | uPAR inhibitor |
|
| B46 | VEGF/osteopotin | Mono | DNP | anti-VEGF and anti-osteopontin aptamer |
|
| C51 | Folate receptor | Mono | Fc-binding cyclic peptide | Folic acid |
|
| D55 | PSMA | Mono | DNP | Glutamate urea |
|
| E56 | αvβ3 integrins | Multi | l-Rha | cRGD |
|
Example of ARMs using unspecific targeting of the cancer cell membrane with lipid anchor.
| Entry | Tumor target | ARM valency | ABM | TBM | ARM structure |
|---|---|---|---|---|---|
| A12 | uPAR | Multi | l-Rha | CholA anchor |
|
| B65 | VEGF/osteopotin | Multi | DNP | Di-alkyl anchor |
|
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.